What a difference three short years can make. Flashback to 2023, and Irish-American pharmaceutical giant Mallinckrodt was reeling a year after emerging from examinership and Chapter 11 bankruptcy in the United States.  A $1.3 billion (€1.13 billion) debt writedown and a settlement of litigation claims involving thousands of US opioid victims was meant to rehabilitate the drugmaker. Instead, Ebitda dropped by 30 per cent year-on-year and the Dublin-headquartered group had to apply to be saved for a second time. Round two saw a US court approve a pre-pack rescue plan where Mallinckrodt’s primary lenders took over the manufacturer in a…

Want to continue reading?

Join today with an Annual membership and unlock full access to The Currency and The Wall Street Journal for just €200 – two premium memberships, one subscription.

Subscribe

Cancel at any time.

Are you already a member? .